Literature DB >> 17485284

An insight into the pathophysiology of thrombosis in antiphospholipid syndrome.

Ivan G Palomo1, Fabian M Segovia, Marcelo L Alarcon, Barbara Y Fuentes, Jaime G Pereira, Armando Rojas, Ricardo Forastiero.   

Abstract

The antiphospholipid syndrome (APS) is a disorder which is characterized by the presence of autoimmune antiphospholipid antibodies (APL) and increased risk of thrombosis and fetal loss. APL are associated with recurrent abortions in APS patients and participate in the pathogenesis of venous or arterial thrombosis, although the underlying mechanisms are poorly understood. Antigens that are targeted by APL include beta 2 glycoprotein I and prothrombin. Pathological mechanisms of APL encompass inhibition of natural anticoagulants (protein C system, tissue factor pathway inhibitor, and annexin A5), inhibition of the fibrinolytic system, activation of endothelial cells, monocytes and platelets, and complement activation. In this review, we discuss the main targets of APL and prothrombogenic mechanisms of APL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17485284     DOI: 10.2741/2297

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  5 in total

1.  Reproductive immunology: current status and future directions (part I).

Authors:  Elena Peeva
Journal:  Clin Rev Allergy Immunol       Date:  2010-12       Impact factor: 8.667

2.  Maternal serum proteome changes between the first and third trimester of pregnancy in rural southern Nepal.

Authors:  P F Scholl; R N Cole; I Ruczinski; M Gucek; R Diez; A Rennie; C Nathasingh; K Schulze; P Christian; J D Yager; J D Groopman; K P West
Journal:  Placenta       Date:  2012-03-03       Impact factor: 3.481

3.  Drug treatment-induced downregulation of antiphospholipid antibodies in PAPS.

Authors:  Ingrid Boehm
Journal:  Clin Rheumatol       Date:  2009-08-20       Impact factor: 2.980

4.  Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases.

Authors:  Koji Habe; Hideo Wada; Takeshi Matsumoto; Kohshi Ohishi; Makoto Ikejiri; Kimiko Matsubara; Tatsuhiko Morioka; Yuki Kamimoto; Tomoaki Ikeda; Naoyuki Katayama; Tsutomu Nobori; Hitoshi Mizutani
Journal:  Int J Hematol       Date:  2013-02-03       Impact factor: 2.490

5.  Decreased levels of circulating CD4+CD25+Foxp3+ regulatory T cells in patients with primary antiphospholipid syndrome.

Authors:  Ester Rosári Raphaelli Dal Ben; Carine Hartmann do Prado; Talita Siara Almeida Baptista; Moisés Evandro Bauer; Henrique Luiz Staub
Journal:  J Clin Immunol       Date:  2013-01-29       Impact factor: 8.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.